Invivyd, Inc. Share Price

Equities

IVVD

US00534A1025

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 19/07/2024 BST 5-day change 1st Jan Change
1.15 USD -5.74% Intraday chart for Invivyd, Inc. -3.36% -70.81%
Sales 2024 * 170M 13.15B Sales 2025 * 326M 25.22B Capitalization 137M 10.63B
Net income 2024 * -116M -8.99B Net income 2025 * -15M -1.16B EV / Sales 2024 * -0.31 x
Net cash position 2024 * 190M 14.7B Net cash position 2025 * 261M 20.18B EV / Sales 2025 * -0.38 x
P/E ratio 2024 *
-1.24 x
P/E ratio 2025 *
-7.04 x
Employees 95
Yield 2024 *
-
Yield 2025 *
-
Free-Float 81.81%
More Fundamentals * Estimated data
Dynamic Chart
1 day-5.74%
1 week-3.36%
Current month+4.55%
1 month-17.86%
3 months-50.00%
6 months-75.53%
Current year-70.81%
More quotes
1 week
1.15
Extreme 1.15
1.48
1 month
1.05
Extreme 1.05
1.63
Current year
1.05
Extreme 1.05
5.20
1 year
1.05
Extreme 1.05
5.20
3 years
0.98
Extreme 0.9802
78.82
5 years
0.98
Extreme 0.9802
78.82
10 years
0.98
Extreme 0.9802
78.82
More quotes
Managers TitleAgeSince
Chief Executive Officer 51 31/08/23
Chief Tech/Sci/R&D Officer 55 11/04/23
Chief Tech/Sci/R&D Officer 55 28/02/23
Members of the board TitleAgeSince
Director/Board Member 68 30/09/20
Director/Board Member 43 24/07/23
Director/Board Member 43 19/10/22
More insiders
Date Price Change Volume
19/07/24 1.15 -5.74% 272,891
18/07/24 1.22 -3.17% 235,191
17/07/24 1.26 -9.35% 348,957
16/07/24 1.39 +7.75% 574,000
15/07/24 1.29 +8.40% 324,954

Delayed Quote Nasdaq, July 19, 2024 at 09:00 pm

More quotes
Invivyd, Inc. is a commercial-stage company, which is engaged in delivering antibody-based therapies. The Company’s proprietary INVYMAB platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to keep pace with evolving viral threats. The Company delivers antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, such as SARS-CoV-2 (COVID-19). Its PEMGARDA is the Company’s first mAb in a planned series of innovative mAb candidates designed to keep pace with SARS-CoV-2 viral evolution. Its VYD2311 is optimized for neutralization potency against recent SARS-CoV-2 lineages such as BA.2.86 and JN.1. The Company also has additional anti-SARS-CoV-2 mAb candidates in discovery and pre-clinical characterization.
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
1.15 USD
Average target price
9.225 USD
Spread / Average Target
+702.17%
Consensus